Health commissioner warns committee higher-potency cannabis could raise youth mental-health risks

Commissioner Helgeland (introduced by the Chair) told the Senate committee that recent public-health evidence points to an association between higher-potency THC products and increased risk of psychosis and other adverse mental-health outcomes in youth. He described anecdotal clinical impressions from therapeutic programs and cited a recent longitudinal California study of youth suggesting a dose–response relationship between cannabis exposure and later psychosis risk.

The commissioner urged caution about raising statewide potency caps, arguing that legalization’s role is to move consumers from an illicit to a regulated market with protective limits. Committee members countered that neighboring states have higher or no caps and asked the commissioner to provide comparative evidence about public-health outcomes in those states. Members also probed whether the Department had data on pediatric poisonings and whether increases in availability would meaningfully change youth access despite age restrictions.

The committee paused further action on potency increases pending a follow-up submission from the Department comparing outcomes in states that raised or removed caps, and asked the commissioner to return with additional analysis and references to the studies he cited.